Biopharmaceutical CMO & CRO Market Is Projected To Grow Due To Significant Growth In Biologics Pipeline Till 2025: Grand View Research, Inc.
The global biopharmaceutical CMO & CRO (contract manufacturing &
research) market is expected to reach USD 37.8 billion by 2025,
according to a new report by Grand View Research, Inc. Healthy outlook of
biopharmaceuticals and consequent growth in biopharmaceutical pipelines has
resulted into lack of adequate capacity and budget constraints. These factors
have convinced many traditional drug developers to take advantage of cost-saving
benefits associated with contract services. Traditional biopharmaceutical
players are observed to choose outsourcing biopharmaceutical manufacturing
rather than making an investment of expensive capital in production equipment
and hiring skilled labor.
Significant improvement in the
services offered by this CMOs/CROs in context to maturity of complex technology
is spurring the adoption of these services. In addition, wide acceptance of
single-use technology within CMOs/CROs has significantly transformed the
CMOs/CROs landscape by enhancing their capabilities and enabling them to
develop products at low operating costs.
Outsourcing services are observed
to play critical role in overcoming trade barriers for firms. It enables them
to make footprints in foreign market where government regulates to secure local
employment through domestic production. Furthermore, as a result of growing
demand for these services, smaller companies have also begun to expand their
non-GMP facilities.
Germany biopharmaceutical
market, by contract manufacturing service, 2014 - 2025 (USD Million)
Browse full research report on
Biopharmaceutical
CMO & CRO Market
Further key findings from
the report suggest:
- Mammalian
cell line-based bioproduction system dominated the share in 2016 in terms
of revenue generation
- This can be
attributed to the presence of substantial number of mammalian-based
manufacturing platforms offered by market leaders such as Lonza, Samsung
BioLogics, WuXi Biologics
- CMOs are
providing wide range of services for entire chain of biopharmaceutical
manufacturing process, consequently held the largest share
- Growing
R&D investment in bioproduction is the high impact rendering factor
for the growth of CROs
- Robust
biologics pipeline and high production cost of biologics have contributed
to the largest share of biologics outsourcing
- Monoclonal
antibodies accounted for significant share in 2016 owing to the huge
success rate of MAbs for disease treatment
- North America
is home to large number of biopharmaceutical manufacturing entities, which
in turn, have resulted into large share of this region
- Being a lower
wage country, China and India are expected to be fastest growing regional
market
- Several
global companies are translocating their business to Asia Pacific owing to
low manufacturing costs in Asian countries
- Boehringer
Ingelheim GmbH, Lonza, Samsung BioLogics, Patheon, FUJIFILM Diosynth
Biotechnologies U.S.A., Inc. are some of the major companies operating in
this space
Comments
Post a Comment